Next-Generation Sequencing Technologies Market

How Big Will the NGS Technologies Market Be by 2033?

The global next-generation sequencing technologies market size is expected to be valued at US$ 13.81 billion in 2026 and projected to reach US$ 35.63 billion by 2033, growing at a CAGR of 14.5% between 2026 and 2033.

Between 2020 and 2025, the market grew at a CAGR of about 11.8%, as pandemic genomic surveillance expanded installed capacity, followed by a slowdown in 2023 and 2024 when research budgets tightened. Three factors now drive growth: falling cost per genome that opens new clinical and population uses, rapid adoption of genomic testing in oncology and rare diseases, and new technologies such as long-read and protein sequencing. The market is moving from a single dominant technology toward competition among short-read, long-read, and new chemistry platforms. Clinical laboratories are becoming the main growth engine as testing moves into routine care.

• By Offering: Products held 72.8% share in 2026, while Services are projected to expand at an 18.8% CAGR through 2033, driven by outsourcing of sequencing and data analysis.
• By Technology: Sequencing by Synthesis held 68.4% share in 2026, while Long-read Sequencing is projected to expand at a 19.6% CAGR through 2033, driven by structural variant detection and complete genome assembly.
• By Application: Oncology held 32.4% share in 2026, while Consumer Genomics is projected to expand at a 17.9% CAGR through 2033, driven by direct-to-consumer whole-genome and health testing.
• By End User: Academic & Research Institutes held 35.6% share in 2026, while Hospitals & Clinical Laboratories are projected to expand at a 17.2% CAGR through 2033, driven by in-house genomic diagnostics.
• By Region: North America held 42.5% share in 2026, while Asia Pacific is projected to expand at a 17.6% CAGR through 2033, driven by domestic sequencing platforms in China and genomics programs in India.

Two drivers carry the strongest influence on next-generation sequencing technologies demand during the forecast period.

Falling Cost Per Genome Is Driving Next-Generation Sequencing Adoption

Falling cost per genome is the strongest driver of next-generation sequencing adoption. Cheaper sequencing makes large studies and routine clinical testing affordable, expanding the number of samples sequenced.

The mechanism is intense technology competition. Illumina’s NovaSeq X brought whole genome sequencing costs to a few hundred dollars per genome. Ultima Genomics and Element Biosciences introduced new platforms promising lower costs, while MGI Tech offers competitive systems in Asia Pacific and beyond. In February 2025, Roche unveiled its Sequencing by Expansion technology, aiming for very fast, high-throughput sequencing. Lower costs allow population programs, biobanks, and pharmaceutical companies to sequence hundreds of thousands of genomes. Researchers also use sequencing for single-cell, spatial, and epigenetic studies. Each cost reduction expands demand for instruments, flow cells, and reagents, supporting overall market growth.

Clinical Adoption Is Expanding Next-Generation Sequencing Technologies

Clinical adoption in oncology, rare diseases, and reproductive health is expanding next-generation sequencing technologies. Genomic results now guide treatment decisions for many patients.

The cause is growing evidence, guidelines, and reimbursement. Comprehensive genomic profiling identifies mutations that match cancer patients to targeted therapies and immunotherapies. Liquid biopsy detects tumor DNA in blood for treatment selection and monitoring. Rapid whole-genome sequencing diagnoses critically ill newborns, often changing care. Non-invasive prenatal testing screens pregnancies for chromosomal conditions. In the United States, Medicare covers NGS-based tests for advanced cancer, and England’s NHS Genomic Medicine Service offers genome sequencing for rare diseases and cancers. Clinical genomics labs increasingly bring testing in-house with benchtop and high-throughput sequencers, creating strong demand for regulated, reliable, and easy-to-use systems.

Two restraints limit how quickly next-generation sequencing technologies are adopted.

Data Burdens and Interpretation Challenges Limit NGS Technology Adoption

Data analysis, storage, and interpretation burdens limit next-generation sequencing technology adoption. Sequencers generate huge datasets that require computing power, storage, and expert interpretation.

The specific causes are data volume and skills shortages. A single human genome produces large data files, and high-throughput sequencers can generate terabytes per run. Labs must invest in servers, cloud storage, cybersecurity, and bioinformatics pipelines. Interpreting variants requires geneticists and curated databases, and many findings remain variants of uncertain significance. Clinical labs must validate workflows and meet quality standards such as CLIA and ISO 15189. Privacy rules such as HIPAA and the General Data Protection Regulation add compliance costs. Smaller hospitals and labs in emerging markets often lack these resources, slowing adoption beyond large academic and reference centers. Cloud platforms help but add recurring costs.

Funding Cuts and Trade Tensions Restrict NGS Technology Growth

Research funding cuts, trade tensions, and reimbursement gaps restrict next-generation sequencing technology growth. Academic labs and biotech companies are major buyers, and their budgets affect instrument purchases.

The underlying causes are budget pressures and geopolitics. Biotech funding fell from pandemic highs, and in 2025, proposed cuts and grant disruptions at the National Institutes of Health created uncertainty for U.S. research labs. In February 2025, China’s Ministry of Commerce added Illumina to its unreliable entity list and later restricted its sequencer exports to China, accelerating a shift to domestic suppliers. The U.S. BIOSECURE Act debate targeted Chinese genomics companies. Many countries still lack reimbursement for genomic tests, limiting clinical use. Instrument purchases are highly capital-intensive, so customers delay upgrades when budgets tighten, creating uneven quarterly demand.

Long-read and Multi-omics Sequencing Open a Premium Technology Revenue Pool

Long-read and multi-omics sequencing open a premium technology revenue pool in the next-generation sequencing technologies market. These methods reveal information that short reads miss, such as complex structural variants and epigenetic changes.

Companies offering long-read sequencing and integrated multi-omics platforms can capture this demand. Pacific Biosciences HiFi sequencing and Oxford Nanopore nanopore sequencing read long DNA fragments accurately, enabling complete genome assembly and detection of repeat expansions. In October 2024, Pacific Biosciences launched its Vega benchtop long-read system to reach more labs. Sequencing-based proteomics expands the market further: in June 2025, Illumina agreed to acquire SomaLogic to add protein analysis. Rare disease centers, cancer researchers, plant and animal genomics groups, and pharmaceutical companies are key customers willing to pay premium prices.

Population Genomics and Precision Medicine Programs Create a Large-volume Revenue Pool

Population genomics and precision medicine programs create a large-volume revenue pool for sequencing technologies. Governments are sequencing large parts of their populations to improve healthcare and research.

Platform providers and sequencing services companies can capture this demand. Programs such as UK Biobank, Genomics England, the All of Us program in the United States, the Saudi Genome Program, Emirati Genome Programme, and GenomeIndia sequence hundreds of thousands of genomes. Newborn genome screening pilots in the United Kingdom and the United States could expand testing dramatically. Pharmaceutical companies fund sequencing of biobank participants to discover drug targets. National health agencies, biobanks, and drug developers are the main customers. These large projects require high-throughput platforms, multi-year reagent contracts, and data infrastructure, creating stable, long-term revenue.

By Offering: Products Lead While Services Gain Momentum

Products held 72.8% share in 2026. Instruments, flow cells, reagents, and consumables make up most spending, with consumables generating recurring revenue from each run. Illumina, Thermo Fisher Scientific, Pacific Biosciences, Oxford Nanopore, and MGI Tech sell platforms and consumables globally.

Services are the fastest-growing offering, expanding at an 18.8% CAGR through 2033. Many hospitals, biotech firms, and research groups outsource sequencing to service providers instead of buying expensive instruments. Providers offer whole-genome, exome, RNA, and single-cell sequencing with data analysis. Large genome centers and companies such as BGI Genomics, Novogene, and Azenta process high volumes at low cost. Clinical testing labs also provide sequencing as a service. For the market, services growth broadens access and shifts revenue toward providers with scale and data expertise.

By Technology: Sequencing by Synthesis Leads While Long-read Sequencing Grows Fastest

Sequencing by Synthesis held 68.4% share in 2026. Illumina’s short-read sequencing by synthesis technology dominates research and clinical sequencing because of its accuracy, throughput, and large installed base. Element Biosciences and others also use related chemistry.

Long-read Sequencing is the fastest-growing technology, expanding at a 19.6% CAGR through 2033. Single-molecule real-time sequencing and nanopore sequencing detect structural variants, repeat expansions, and methylation directly. Falling costs and higher accuracy make long reads practical for clinical genomics and complete genome assembly. Ion semiconductor sequencing, DNA nanoball sequencing, and new chemistries such as sequencing by expansion add competition. For the market, long-read growth diversifies technology choices and supports premium applications in clinical and research genomics.

By Application: Oncology Leads While Consumer Genomics Grows Fastest

Oncology held 32.4% share in 2026. Tumor profiling, liquid biopsy, hereditary cancer testing, and cancer research use sequencing heavily. Targeted therapies and immunotherapies depend on genomic biomarkers, supporting strong demand.

Consumer Genomics is the fastest-growing application, expanding at a 17.9% CAGR through 2033. Lower costs allow companies to offer whole-genome sequencing directly to consumers for ancestry, wellness, and health risk information. Consumers increasingly share data with healthcare providers and research programs, and some employers and insurers offer genome testing as a wellness benefit. Pharmacogenomic results can also guide medication choices. Reproductive health, rare disease diagnosis, infectious disease, and agrigenomics remain important applications. For the market, consumer genomics growth expands sequencing beyond clinical settings but raises privacy and interpretation questions.

By End User: Academic & Research Institutes Lead While Hospitals & Clinical Laboratories Grow Fastest

Academic & Research Institutes held 35.6% share in 2026. Universities, genome centers, and government research institutes perform large-scale studies in genetics, cancer, neuroscience, and microbiology. Research grants fund instruments and consumables.

Hospitals & Clinical Laboratories are the fastest-growing end user, expanding at a 17.2% CAGR through 2033. More hospitals are bringing oncology, rare disease, and infectious disease testing in-house to speed results and control costs. Benchtop sequencers with automated workflows make clinical sequencing practical for mid-sized labs. Expanding reimbursement and updated clinical guidelines support wider adoption. Pharmaceutical and biotechnology companies remain major users for drug discovery and clinical trials. For the market, clinical growth shifts demand toward regulated, reliable systems with strong service support.

Which Region Is Leading the Next-Generation Sequencing Technologies Market?

North America is leading the next-generation sequencing technologies market with a 42.5% share in 2026. The United States hosts leading sequencing companies, including Illumina, Thermo Fisher Scientific, Pacific Biosciences, Element Biosciences, and Ultima Genomics. Large research funding, pharmaceutical investment, and clinical testing labs drive demand. Medicare coverage supports cancer genomic testing, and the All of Us program sequences diverse populations. Canada adds research demand through Genome Canada and provincial cancer agencies. Biotech hubs in Boston, San Diego, and San Francisco are major customers. One change shaping the region is competition from new low-cost platforms challenging established players.

Europe Expands Next-Generation Sequencing Through Genomic Medicine Programs

Europe is a major next-generation sequencing technologies market supported by genomic medicine programs. Genomics England and the NHS Genomic Medicine Service have made the United Kingdom a leader in clinical genome sequencing. France, Germany, the Netherlands, and the Nordic countries invest in precision medicine and biobanks. Oxford Nanopore Technologies in the United Kingdom and Roche in Switzerland develop sequencing technologies. The In Vitro Diagnostic Regulation raises evidence requirements for clinical tests. Public tenders and reimbursement differences across countries create uneven adoption, with the United Kingdom, France, and the Netherlands moving fastest. One opportunity is cross-border genomic data sharing.

Which Region Is Growing Fastest in the Next-Generation Sequencing Technologies Market?

Asia Pacific is growing fastest in the next-generation sequencing technologies market at a 17.6% CAGR through 2033. China has large sequencing capacity through BGI Group and MGI Tech, and restrictions on Illumina are accelerating domestic platform adoption. India’s GenomeIndia project and private diagnostics labs drive demand. Japan and South Korea run cancer genome and biobank programs, while Singapore invests in precision medicine. Rising healthcare spending, a large cancer burden, and growing private diagnostics chains support adoption. Australia also runs national genomic medicine initiatives. One opportunity is lower-cost platforms and kits for fast-growing hospital and private clinical labs.

Latin America Builds Next-Generation Sequencing Capacity in Oncology and Research

Latin America is an emerging next-generation sequencing technologies market where oncology testing, research, and pathogen surveillance drive demand. Brazil and Mexico have the region’s largest sequencing labs, including private diagnostic companies and large public research institutes. Argentina, Chile, and Colombia use sequencing in research, agriculture, and aquaculture. Pandemic-era investments left many public labs with sequencing capacity that is now used for routine surveillance of pathogens. Key barriers include high import costs, currency volatility, limited reimbursement, few bioinformatics specialists, and long equipment service response times. One opportunity is sequencing services that give smaller labs access to genomics.

Middle East & Africa Invests in Next-Generation Sequencing Through National Genome Programs

Middle East & Africa is a developing next-generation sequencing technologies market where national genome programs drive investment. Saudi Arabia, the United Arab Emirates, and Qatar run large population sequencing programs and are building genomic medicine services. In Africa, South Africa, Nigeria, and Kenya use sequencing for pathogen surveillance and research. Key barriers include limited infrastructure, skills, and funding. International partners such as the Africa CDC pathogen genomics initiative have helped build sequencing capacity across the continent. Gulf hospitals are steadily adding in-house clinical sequencing. One opportunity is genomic research on underrepresented African populations.

The next-generation sequencing technologies market is highly concentrated. Illumina holds the largest share through its short-read platforms and installed base, while Thermo Fisher Scientific, Pacific Biosciences, Oxford Nanopore Technologies, and MGI Tech compete in specific segments. New entrants such as Element Biosciences, Ultima Genomics, and Roche with its sequencing by expansion technology are increasing competition.

Companies mainly compete on cost per genome, accuracy, read length, throughput, speed, ease of use, and clinical regulatory status. Consumables lock-in creates recurring, high-margin revenue for platform owners. Service providers compete on price, turnaround time, quality, and data analysis. Geopolitical factors increasingly shape supplier choices in China and the United States. Software, data analysis tools, and cloud partnerships are becoming important differentiators as customers seek complete sample-to-answer solutions. Pricing pressure from new entrants has pushed established vendors to cut consumables prices and offer flexible instrument financing.

Strategic moves show how competition is changing. In October 2024, Pacific Biosciences launched its Vega benchtop long-read system. In February 2025, Roche unveiled its sequencing by expansion technology, signaling its return to sequencing. In June 2025, Illumina agreed to acquire SomaLogic to expand into proteomics. These moves show competition shifting toward new chemistries, long reads, and multi-omics.

Three themes shape vendor strategy. First, companies are lowering cost per genome through new chemistries and higher throughput. Second, they are expanding into regulated clinical markets. Third, they are adding proteomics and multi-omics capabilities.

Next-Generation Sequencing Technologies Market Industry Leaders

• Illumina
• Thermo Fisher Scientific
• Pacific Biosciences
• Oxford Nanopore Technologies
• BGI Group (MGI Tech)

Recent Industry Developments

June 2025: Illumina agreed to acquire SomaLogic - expands into protein analysis and multi-omics.

February 2025: Roche unveiled its sequencing by expansion technology - adds a major new competitor.

February 2025: China’s Ministry of Commerce added Illumina to its unreliable entity list - accelerates domestic sequencer adoption in China.

October 2024: Pacific Biosciences launched its Vega benchtop long-read system - broadens access to long-read sequencing.

This report covers next-generation sequencing products and services, including sequencing instruments, consumables, and sequencing services, across sequencing by synthesis, long-read, ion semiconductor, and other technologies, used in oncology, reproductive health, rare diseases, research, and consumer genomics. It excludes standalone library preparation kits sold separately, bioinformatics software, and Sanger sequencing. The base year is 2025, and the forecast period runs from 2026 to 2033. All values are expressed in US$ Billion.

Offering

• Products
• Services

Technology

• Sequencing by Synthesis
• Long-read Sequencing
• Ion Semiconductor Sequencing
• Others

Application

• Oncology
• Reproductive Health
• Rare & Inherited Diseases
• Infectious Diseases
• Consumer Genomics
• Others

End User

• Academic & Research Institutes
• Hospitals & Clinical Laboratories
• Pharmaceutical & Biotechnology Companies
• Others

Regions

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa